Company profile: LadRx
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapeutics leveraging LADR (Linker Activated Drug Release) technology to bind anti-cancer molecules to albumin and release cytotoxic payloads at tumors, enabling higher doses with minimized off-target toxicity. Portfolio includes Aldoxorubicin, next-generation LADR-7, and Arimoclomol to amplify heat-shock proteins against protein misfolding, aggregation, and lysosomal dysfunction.
Products and services
- LADR™ (Linker Activated Drug Release) Technology: A tumor-targeted platform that binds anti-cancer molecules to circulating albumin and releases cytotoxic payloads at tumor sites, enabling higher intra-tumor doses while minimizing off-target toxicity
- Aldoxorubicin: A rationally-engineered cytotoxic drug that delivers doxorubicin into tumors, aiming to overcome the limitations of doxorubicin, including cumulative dose restrictions
- LADR-7: A GMP-manufactured, next-generation LADR drug ready for IND filing in 3Q–4Q 2024 and FIH end of 2024
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to LadRx
Celleron Therapeutics
HQ: United Kingdom
Website
- Description: Provider of oncology therapeutics and biomarker-driven precision medicine, developing epigenetic biomarkers to match drugs to responsive disease. Pipeline includes Zabadinostat, an immune modulator with clinical activity in colorectal cancer, liver cancer, and lymphoma; PCV-001, a preclinical precision cancer vaccine; and AT-101, an in-house PRMT5 inhibitor in clinical planning.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Celleron Therapeutics company profile →
Stemcentrx
HQ: United States
Website
- Description: Provider of disease-specific cancer therapies that target tumors at their roots to cure and significantly improve survival for patients, offering pharmaceutical services. Operates as a subsidiary of AbbVie.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stemcentrx company profile →
Adze Biotech
HQ: United States
Website
- Description: Provider of pre-clinical oncolytic immunotherapies for cancer, including a chimeric adenoviral platform for systemic delivery of immune-stimulatory transgenes and checkpoint inhibitors to distant and local tumors. Pipeline includes Adze-1.17, which selectively kills tumor cells and releases tumor-derived antigens; Adze-1.17-CD40L for malignant glioma; and Ad657, a recombinant adenovirus with intratumoral and systemic potential across broad malignancies and solid tumor indications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adze Biotech company profile →
Molecular Templates
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for cancer and other serious diseases, leveraging a proprietary engineered toxin body (ETB) platform with unique mechanisms of action. Pipeline includes MT-6402 (PD-L1), MT-8421 (CTLA-4), and MT-0169 (CD38). Operates a multi-product cGMP manufacturing facility in Austin, TX to supply clinical trial materials for internal and partnered ETB programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Molecular Templates company profile →
Eclipse Therapeutics
HQ: United States
Website
- Description: Provider of therapeutics discovery and development targeting cancer stem cells (CSCs) and other innovative cancer treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eclipse Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for LadRx
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to LadRx
2.2 - Growth funds investing in similar companies to LadRx
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for LadRx
4.2 - Public trading comparable groups for LadRx
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →